Janux Therapeutics Statistics
Total Valuation
JANX has a market cap or net worth of $2.45 billion. The enterprise value is $1.82 billion.
| Market Cap | 2.45B |
| Enterprise Value | 1.82B |
Important Dates
The last earnings date was Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
JANX has 51.85 million shares outstanding. The number of shares has increased by 17.45% in one year.
| Shares Outstanding | 51.85M |
| Shares Change (YoY) | +17.45% |
| Shares Change (QoQ) | +5.00% |
| Owned by Insiders (%) | 9.50% |
| Owned by Institutions (%) | 98.98% |
| Float | 19.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 336.14 |
| Forward PS | n/a |
| PB Ratio | 3.74 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 249.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 62.09, with a Debt / Equity ratio of 0.04.
| Current Ratio | 62.09 |
| Quick Ratio | 61.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -13.50% and return on invested capital (ROIC) is -10.72%.
| Return on Equity (ROE) | -13.50% |
| Return on Assets (ROA) | -12.40% |
| Return on Capital (ROIC) | -10.72% |
| Revenue Per Employee | $107,162 |
| Profits Per Employee | -$817,559 |
| Employee Count | 68 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +292.50% in the last 52 weeks. The beta is 3.87, so JANX's price volatility has been higher than the market average.
| Beta (1Y) | 3.87 |
| 52-Week Price Change | +292.50% |
| 50-Day Moving Average | 45.97 |
| 200-Day Moving Average | 20.17 |
| Relative Strength Index (RSI) | 44.16 |
| Average Volume (30 Days) | 1,159,690 |
Short Selling Information
The latest short interest is 3.30 million, so 6.37% of the outstanding shares have been sold short.
| Short Interest | 3.30M |
| Short Previous Month | 3.44M |
| Short % of Shares Out | 6.37% |
| Short % of Float | 16.67% |
| Short Ratio (days to cover) | 3.77 |
Income Statement
In the last 12 months, JANX had revenue of $7.29 million and -$55.59 million in losses. Loss per share was -$1.21.
| Revenue | 7.29M |
| Gross Profit | 7.29M |
| Operating Income | -72.86M |
| Pretax Income | -55.59M |
| Net Income | -55.59M |
| EBITDA | -53.56M |
| EBIT | -55.59M |
| Loss Per Share | -$1.21 |
Balance Sheet
The company has $652.58 million in cash and $24.19 million in debt, giving a net cash position of $628.39 million or $12.12 per share.
| Cash & Cash Equivalents | 652.58M |
| Total Debt | 24.19M |
| Net Cash | 628.39M |
| Net Cash Per Share | $12.12 |
| Equity / Book Value | 655.76M |
| Book Value Per Share | 12.65 |
| Working Capital | 648.06M |
Cash Flow
In the last 12 months, operating cash flow was -$51.50 million and capital expenditures -$1.76 million, giving a free cash flow of -$53.26 million.
| Operating Cash Flow | -51.50M |
| Capital Expenditures | -1.76M |
| Free Cash Flow | -53.26M |
| FCF Per Share | -$1.09 |
Margins
Gross margin is 100.00%, with operating and profit margins of -999.85% and -762.92%.
| Gross Margin | 100.00% |
| Operating Margin | -999.85% |
| Pretax Margin | -762.92% |
| Profit Margin | -762.92% |
| EBITDA Margin | -735.01% |
| EBIT Margin | -762.92% |
| FCF Margin | -730.93% |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.45% |
| Shareholder Yield | -17.45% |
| Earnings Yield | -2.27% |
| FCF Yield | -2.17% |
Analyst Forecast
The average price target for JANX is $67.14, which is 42.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $67.14 |
| Price Target Difference | 42.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 70.95% |
| EPS Growth Forecast (5Y) | 14.56% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
JANX has an Altman Z-Score of 44.74 and a Piotroski F-Score of 3.
| Altman Z-Score | 44.74 |
| Piotroski F-Score | 3 |